Mirabegron Aspire

Mirabegron, the active ingredient in Mirabegron Aspire, is a beta‑3 adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency, and urge urinary incontinence in adult patients.

GNH USA supplies Mirabegron Aspire as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand with reliable logistics and documentation support.

Mirabegron, a beta‑3 adrenergic receptor agonist, is used in the management of overactive bladder and related lower urinary tract symptoms.

Overactive bladder: improves bladder storage capacity and reduces urgency episodes. Urinary urgency: lessens the frequency of sudden urges to void. Urge urinary incontinence: decreases episodes of involuntary leakage. Frequency: lowers the number of daytime voids. Nocturia: may reduce nighttime awakenings to urinate.

Adverse reactions reported with mirabegron use are categorized by frequency.

Common Side Effects: - Hypertension: increase in blood pressure, often mild. - Nasopharyngitis: inflammation of the nasal passages and throat. - Urinary tract infection: symptoms of dysuria or frequency. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Severe hypertension: marked elevation of blood pressure requiring medical attention. - Angioedema: swelling of face, lips, or airway. - Myocardial infarction: rare cardiac event reported in some patients.

When prescribing mirabegron, clinicians should consider several safety factors.

Cardiovascular assessment: monitor blood pressure before and during therapy. Renal function: adjust use in severe renal impairment. Hepatic impairment: use with caution in moderate to severe liver disease. Concomitant medications: review drugs that affect β3 receptors or CYP2D6 metabolism. Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture and light.

Mirabegron may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Co‑administration with other β3 agonists: risk of additive pharmacologic effects.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): possible increased plasma levels. - Diuretics: may augment risk of hypertension. - Anticholinergic agents: may reduce mirabegron efficacy on bladder symptoms.